Orrick advised Catalyst Biosciences, Inc. on the deal.South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced the sale of its complement asset portfolio for $60…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
